Insulet | PODD - Des Atouts





Des Atouts Changement Date
Abbott USD 110.43B 23.72B 2026-03
Align Technology USD 6.42B 103.41M 2026-06
AtriCure USD 676.64M 32.66M 2026-06
Baxter International USD 19.79B 55M 2026-06
Becton, Dickinson and Co. USD 50.73B 101M 2026-06
Boston Scientific USD 45.22B 865M 2026-06
Cardinal Health USD 57.3B 610M 2026-06
Cooper Companies USD 12.48B 58.1M 2026-03
Dexcom USD 6.46B 178M 2026-06
Edwards Lifesciences USD 13.87B 545.9M 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Globus Medical USD 5.49B 48.7M 2026-06
ICU Medical USD 3.97B 42.48M 2026-06
Inogen USD 307.01M 5.03M 2025-09
Insulet USD 3.17B 177.9M 2026-06
Integra LifeSciences USD 3.56B 14.24M 2026-06
J&J USD 201.06B 167M 2026-06
Medtronic USD 91.48B 139M 2025-12
Merit Medical Systems USD 2.86B 144.34M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Solventum Corp USD 14.24B 146M 2026-06
Stryker USD 47.93B 1.64B 2026-06
Tandem Diabetes Care USD 1.15B 808K 2026-06
Teleflex USD 6.79B 3.78M 2026-06
West Pharmaceutical Services USD 4.08B 33.4M 2026-06
Zimmer Biomet Holdings USD 22.8B 76.2M 2026-06